Health and Healthcare
Why Biogen Shares Are Tumbling After Earnings Report
Published:
Last Updated:
On a GAAP basis, the company reported second-quarter EPS of $3.93, which included a gain of $86.8 million for amortization of acquired assets and a $17.1 million tax-related charge.
After commenting on Biogen’s multiple sclerosis and hemophilia treatments, the company’s CEO focused on the company’s trials of an Alzheimer’s disease treatment:
The Company also continues to invest in the science that is core to our future, and we are continuing to advance our pipeline in areas where patients have limited or no treatment options. We are excited to report we are now actively recruiting for two global Phase 3 studies of aducanumab in patients with early Alzheimer’s disease. We see aducanumab as a potentially transformational opportunity for Biogen, and for patients with this devastating disease.
Biogen also updated its full-year financial guidance. Revenue growth is now expected to be in the range of 6% to 8% above 2014 revenues of $9.7 billion. The company’s previous guidance called for revenue growth of 14% to 16% above last year’s revenues. Adjusted EPS guidance also was lowered from a prior range of $16.60 to $17.00 to a new range of $15.50 to $15.95.
The cuts to revenue and earnings guidance will absolutely hammer the share price in Friday trading. Sales of its multiple sclerosis drugs missed analysts’ revenue expectations, and the cuts to guidance indicate that Biogen expects those sales to remain lower than previous estimates.
Biogen shares traded down nearly 12% in premarket trading, at $340.00 in a 52-week range of $290.85 to $480.18. Thomson Reuters had a consensus analyst price target of $471.75 before the report.
ALSO READ: The Worst Companies to Work For
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.